查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370942

治療疫苗市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會與預測，按產品、技術、地區、競爭細分

Therapeutics Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Technology, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 178 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年全球治療性疫苗市場估值為 278.1 億美元，預計在整個預測期內將實現強勁成長，實現 9.68% 的年複合成長率 (CAGR)，到 2028 年達到 483.2 億美元。一種特定類型的疫苗，旨在治療或減輕現有疾病，而不僅僅是預防疾病。與向健康個體注射以預防未來感染的傳統預防性疫苗不同，治療性疫苗是注射給那些已經受到疾病影響的人。目的是激活免疫系統，更有效地針對和對抗疾病。人們越來越認知到治療性疫苗對健康的益處，預計將對全球市場的擴張產生正面影響。

主要市場促進因素：

市場概況
預測期 2024-2028
2022 年市場規模 278.1億美元
2028 年市場規模 483.2億美元
2023-2028 年年複合成長率 9.68%
成長最快的細分市場 自體疫苗
最大的市場 北美洲

1. 疾病負擔的增加推動市場成長：

包括癌症、慢性感染、自體免疫疾病和神經退化性疾病在內的各種疾病負擔的不斷增加，是全球治療性疫苗市場的主要驅動力。隨著越來越多的人受到這些疾病的影響，對治療性疫苗等創新治療解決方案的需求不斷增加。這些疫苗提供了一種解決根本原因的替代方法，其潛在益處超出了現有治療方法。

2.免疫學的進步推動市場成長：

免疫學的進步透過促進開發更有針對性和更有效的治療性疫苗，在推動全球治療性疫苗市場向前發展方面發揮關鍵作用。增強對免疫系統功能的了解有助於疫苗的設計和最佳化。這些知識對於治療性疫苗尤其重要，治療性疫苗旨在引發針對癌細胞或慢性感染病原體等致病因子的免疫反應。

3. 醫療保健支出增加：

醫療保健支出的增加極大地促進了全球治療性疫苗市場的擴張。更高的醫療支出支持醫學研究和開發，從而推動治療性疫苗的進步。強而有力的臨床試驗計畫對於將新疫苗推向市場至關重要，增加資金可以促進這些試驗。充足的資金也促進研究機構、製藥公司和學術中心之間的合作，推動治療性疫苗開發的創新。

主要市場挑戰：

1. 科學複雜性：

由於科學的複雜性，設計和開發有效針對特定疾病的疫苗的複雜性提出了巨大的挑戰。與免疫系統、疾病特徵和疫苗機制相關的各種因素導致了這種複雜性。疾病特異性疫苗設計、個人免疫系統變異以及合適抗原的選擇是疫苗開發的挑戰。

2. 開發時間長：

漫長的開發時間阻礙了新疫苗在市場上的快速供應。這種延遲會影響患者獲得可能挽救生命的治療，並使競爭公司更快推出類似產品，這可能導致錯失市場機會。進展迅速或治療窗口期關鍵的疾病尤其受到影響。

3. 製造挑戰：

製造複雜性影響治療性疫苗的生產、品質和可擴展性。確保一致的產品品質和克服大規模製造中的挑戰至關重要。生產過程的可變性會影響疫苗的功效和性能。某些治療性疫苗可能需要專用設備和設施，這給生產帶來了挑戰。

主要市場趨勢：

1. 奈米技術與藥物傳輸：

奈米技術和藥物傳輸創新是全球治療性疫苗市場的主要趨勢，提供了增強疫苗有效性和標靶輸送的解決方案。奈米技術可以設計新型疫苗配方，提高穩定性、生物利用度和免疫反應。奈米顆粒可以模仿病原體或以更有效地活化免疫系統的方式呈現抗原，可能導致更強、更持久的免疫反應。

2. 細分洞察：

自體免疫疾病疫苗因其在這些複雜條件下調節免疫反應的潛力而佔據市場主導地位。然而，臨床試驗中的挑戰、可變的疾病進展以及現有治療方法的競爭影響了自體免疫疾病疫苗的開發。

3. 技術洞察：

由於更容易製造、標準化和安全性，同種異體疫苗比自體疫苗具有優勢。同種異體疫苗可以更大量地生產並且更廣泛地使用，從而推動其在市場上的主導地位。

區域見解：

1. 北美：

由於持續的癌症流行、研發支出的增加以及健康維護意識的增強，預計北美市場將會成長。該地區癌症的流行可能會推動對治療性癌症疫苗的需求。

2.歐洲：

在其強大的生物製藥產業、成熟的製藥公司和研究機構的推動下，歐洲有望成為成長最快的治療性疫苗市場。歐洲國家在臨床試驗和監管流程方面的經驗支持疫苗開發，促進市場成長。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球治療疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品（自體免疫疾病疫苗、神經疾病疫苗、癌症疫苗、傳染病疫苗、其他）
    • 依技術分類（同種異體疫苗、自體疫苗）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：北美治療疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 依技術
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲治療疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 依技術
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區治療疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 依技術
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲治療疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 依技術
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲治療疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 依技術
  • MEA：國家分析
    • 南非治療疫苗
    • 沙烏地阿拉伯治療疫苗
    • 阿拉伯聯合大公國治療疫苗

第 11 章：臨床試驗分析

第 12 章：市場動態

  • 促進因素與挑戰

第 13 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 14 章：全球治療疫苗市場：SWOT 分析

第15章：競爭格局

  • 商業概覽
  • 技術產品
  • 最近的發展
  • 主要人員
  • SWOT分析
    • genus Inc.
    • Argos Therapeutic Inc.
    • Celldex Therapeutic Inc. (Avant Immunotherapeutics, Inc.)
    • Dendreon Corp (Sanpower Group Co., Ltd.)
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Phio Pharmaceuticals Corp.
    • AstraZeneca PLC
    • BioNTech SE

第 16 章：策略建議

第 17 章：關於我們與免責聲明

簡介目錄
Product Code: 4606

The Global Therapeutics Vaccine Market was valued at USD 27.81 Billion in 2022, and it is projected to experience robust growth throughout the forecast period, achieving a Compound Annual Growth Rate (CAGR) of 9.68% and reached USD 48.32 Billion through 2028. Therapeutics vaccines are a specific type of vaccine designed to treat or mitigate existing diseases rather than solely preventing them. In contrast to conventional preventive vaccines administered to healthy individuals to ward off future infections, therapeutic vaccines are given to those already affected by a disease. The purpose is to activate the immune system to more effectively target and combat the disease. The increasing awareness of the health benefits linked with therapeutic vaccines is expected to positively influence global market expansion.

Therapeutic cancer vaccines are in development to stimulate the immune system to identify and attack cancer cells. These vaccines can complement other cancer treatments like chemotherapy or radiation therapy. The objective is to enhance the body's inherent defense mechanisms to selectively target and eliminate cancer cells, potentially resulting in improved treatment outcomes. Therapeutic vaccines also hold promise in addressing chronic infections such as HIV, hepatitis B, and hepatitis C. These vaccines aim to amplify the immune response against the infectious agent, aiding the body in managing the infection and minimizing its adverse effects. The potential applications of therapeutic vaccines could expand with advancements in medical research and technology. However, their effectiveness and usage rely on rigorous scientific exploration and regulatory approval.

Key Market Drivers:

Market Overview
Forecast Period2024-2028
Market Size 2022USD 27.81 Billion
Market Size 2028USD 48.32 Billion
CAGR 2023-20289.68%
Fastest Growing SegmentAutologous vaccines
Largest MarketNorth America

1. Increasing Disease Burden Drives Market Growth:

The rising burden of various diseases, including cancer, chronic infections, autoimmune disorders, and neurodegenerative conditions, is a major driver for the global therapeutic vaccine market. With a growing number of individuals affected by these diseases, there is a heightened demand for innovative treatment solutions such as therapeutic vaccines. These vaccines offer an alternative approach to addressing underlying causes, offering potential benefits beyond existing treatments.

2. Advances in Immunology Fuel Market Growth:

Progress in immunology plays a pivotal role in propelling the global therapeutic vaccine market forward by enabling the development of more targeted and effective therapeutic vaccines. Enhanced understanding of immune system functions informs the design and optimization of vaccines. This knowledge is especially crucial for therapeutic vaccines, which aim to trigger immune responses against disease-causing agents like cancer cells or chronic infection pathogens.

3. Rising Healthcare Expenditure:

Increased healthcare spending significantly contributes to the expansion of the global therapeutic vaccine market. Higher healthcare expenditure supports medical research and development, leading to advancements in therapeutic vaccines. Robust clinical trial programs are essential for bringing new vaccines to market, and increased funding facilitates these trials. Adequate funding also fosters collaborations among research institutions, pharmaceutical companies, and academic centers, driving innovation in therapeutic vaccine development.

Key Market Challenges:

1. Scientific Complexity:

The intricate nature of designing and developing vaccines that effectively target specific diseases presents a substantial challenge due to scientific complexity. Various factors related to the immune system, disease characteristics, and vaccine mechanisms contribute to this complexity. Disease-specific vaccine design, immune system variability among individuals, and the selection of suitable antigens are among the challenges faced in vaccine development.

2. Long Development Timelines:

Long development timelines hinder the rapid availability of new vaccines in the market. This delay impacts patient access to potentially life-saving treatments and allows competing companies to advance similar products more quickly, potentially leading to missed market opportunities. Diseases with rapid progression or critical treatment windows are particularly affected.

3. Manufacturing Challenges:

Manufacturing complexities affect the production, quality, and scalability of therapeutic vaccines. Ensuring consistent product quality and overcoming challenges in large-scale manufacturing are critical. Variability in manufacturing processes can impact vaccine efficacy and performance. Specialized equipment and facilities may be required for certain therapeutic vaccines, contributing to production challenges.

Key Market Trends:

1. Nanotechnology and Drug Delivery:

Nanotechnology and drug delivery innovations are key trends in the global therapeutic vaccine market, offering solutions to enhance vaccine effectiveness and targeted delivery. Nanotechnology allows for the design of novel vaccine formulations that improve stability, bioavailability, and immune responses. Nanoparticles can mimic pathogens or present antigens in ways that activate the immune system more effectively, potentially leading to stronger and longer-lasting immune responses.

2. Segmental Insights:

Autoimmune disease vaccines dominate the market due to their potential to modulate immune responses in these complex conditions. However, challenges in clinical trials, variable disease progression, and competition from existing treatments impact vaccine development for autoimmune diseases.

3. Technology Insights:

Allogeneic vaccines hold an advantage over autologous vaccines due to easier manufacturing, standardization, and safety. Allogeneic vaccines can be produced in larger quantities and are more widely available, driving their dominance in the market.

Regional Insights:

1. North America:

The North American market is anticipated to grow due to the ongoing cancer epidemic, increasing R&D spending, and growing awareness of health maintenance. The prevalence of cancer in the region will likely drive the demand for therapeutic cancer vaccines.

2. Europe:

Europe is poised to be the fastest-growing market for therapeutic vaccines, driven by its robust biopharmaceutical industry, established pharmaceutical companies, and research institutions. European countries' experience in clinical trials and regulatory processes supports vaccine development, contributing to the growth of the market.

Key Market Players

  • Genus Inc.
  • Argos Therapeutic Inc.
  • Celldex Therapeutic Inc. (Avant Immunotherapeutics, Inc.)
  • Dendreon Corp (Sanpower Group Co., Ltd.)
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Phio Pharmaceuticals Corp.
  • AstraZeneca PLC
  • BioNTech SE

Report Scope:

In this report, the Global Therapeutics Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Therapeutics Vaccine Market, By Product:

  • Autoimmune Disease Vaccines
  • Neurological Disease Vaccines
  • Cancer Vaccines
  • Infectious Disease Vaccines
  • Other

Therapeutics Vaccine Market, By Technology:

  • Allogeneic Vaccine
  • Autologous Vaccine

Therapeutics Vaccine Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Therapeutics Vaccine Market.

Available Customizations:

  • Global Therapeutics Vaccine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Therapeutics Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Autoimmune Disease Vaccines, Neurological Disease Vaccines, Cancer Vaccines, Infectious Disease Vaccines, Other)
    • 5.2.2. By Technology (Allogeneic Vaccine, Autologous Vaccine)
    • 5.2.3. By Region
    • 5.2.4. By Company (2022)
  • 5.3. Market Map

6. North America Therapeutics Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Technology
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Therapeutics Vaccine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Technology
    • 6.3.2. Canada Therapeutics Vaccine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Technology
    • 6.3.3. Mexico Therapeutics Vaccine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Technology

7. Europe Therapeutics Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Technology
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Therapeutics Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Technology
    • 7.3.2. United Kingdom Therapeutics Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Technology
    • 7.3.3. Italy Therapeutics Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Technology
    • 7.3.4. France Therapeutics Vaccine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Technology
    • 7.3.5. Spain Therapeutics Vaccine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Technology

8. Asia-Pacific Therapeutics Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Technology
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Therapeutics Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Technology
    • 8.3.2. India Therapeutics Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Technology
    • 8.3.3. Japan Therapeutics Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Technology
    • 8.3.4. South Korea Therapeutics Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Technology
    • 8.3.5. Australia Therapeutics Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Technology

9. South America Therapeutics Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Technology
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Therapeutics Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Technology
    • 9.3.2. Argentina Therapeutics Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Technology
    • 9.3.3. Colombia Therapeutics Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Technology

10. Middle East and Africa Therapeutics Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Technology
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Therapeutics Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Technology
    • 10.3.2. Saudi Arabia Therapeutics Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Technology
    • 10.3.3. UAE Therapeutics Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Technology

11. Clinical Trial Analysis

12. Market Dynamics

  • 12.1. Drivers & Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Product Launches
  • 13.3. Merger & Acquisition

14. Global Therapeutics Vaccine Market: SWOT Analysis

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Technology Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. genus Inc.
    • 15.5.2. Argos Therapeutic Inc.
    • 15.5.3. Celldex Therapeutic Inc. (Avant Immunotherapeutics, Inc.)
    • 15.5.4. Dendreon Corp (Sanpower Group Co., Ltd.)
    • 15.5.5. GlaxoSmithKline plc
    • 15.5.6. Merck & Co. Inc.
    • 15.5.7. Novartis AG
    • 15.5.8. Pfizer, Inc.
    • 15.5.9. Phio Pharmaceuticals Corp.
    • 15.5.10. AstraZeneca PLC
    • 15.5.11. BioNTech SE

16. Strategic Recommendations

17. About Us & Disclaimer